Literature DB >> 27847366

Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults.

Daniel F Hoft1, Kathleen R Lottenbach2, Azra Blazevic2, Aldin Turan2, Tamara P Blevins2, Thomas P Pacatte2, Yinyi Yu2, Michelle C Mitchell2, Stella G Hoft2, Robert B Belshe2.   

Abstract

Both live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) induce protective immunity against influenza. There is evidence that LAIV induces superior protection in children, whereas IIV may induce superior protection in adults. The immune mechanisms responsible for these differences have not been identified. We previously compared LAIV and IIV in young children of 6 to 36 months of age, and we demonstrated that while both induced similar hemagglutination inhibition (HAI) antibody responses, only LAIV induced significant increases in T cell responses. In the present study, 37 healthy adult subjects of 18 to 49 years of age were randomized to receive seasonal influenza vaccination with LAIV or IIV. Influenza virus-specific HAI, T cell, and secretory IgA (sIgA) responses were studied pre- and postvaccination. In contrast to the responses seen in young children, LAIV induced only minimal increases in serum HAI responses in adults, which were significantly lower than the responses induced by IIV. Both LAIV and IIV similarly induced only transient T cell responses to replication-competent whole virus in adults. In contrast, influenza virus-specific sIgA responses were induced more strongly by LAIV than by IIV. Our previous studies suggest that LAIV may be more protective than IIV in young children not previously exposed to influenza virus or influenza vaccines due to increased vaccine-induced T cell and/or sIgA responses. Our current work suggests that in adults with extensive and partially cross-reactive preexisting influenza immunity, LAIV boosting of sIgA responses to hemagglutinin (HA) and non-HA antigenic targets expressed by circulating influenza virus strains may be an important additional mechanism of vaccine-induced immunity.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  IIV; LAIV; adults; influenza; vaccine

Mesh:

Substances:

Year:  2017        PMID: 27847366      PMCID: PMC5216430          DOI: 10.1128/CVI.00414-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

1.  Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members.

Authors:  Angelia A Eick; Zhong Wang; Hayley Hughes; Stephen M Ford; Steven K Tobler
Journal:  Vaccine       Date:  2009-04-19       Impact factor: 3.641

Review 2.  Mucosal IgA responses in influenza virus infections; thoughts for vaccine design.

Authors:  Elly van Riet; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa
Journal:  Vaccine       Date:  2012-07-24       Impact factor: 3.641

Review 3.  Chemokines and the tissue-specific migration of lymphocytes.

Authors:  Eric J Kunkel; Eugene C Butcher
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

4.  Cellular immune correlates of protection against symptomatic pandemic influenza.

Authors:  Saranya Sridhar; Shaima Begom; Alison Bermingham; Katja Hoschler; Walt Adamson; William Carman; Thomas Bean; Wendy Barclay; Jonathan J Deeks; Ajit Lalvani
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440

5.  Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Authors:  Sanae Sasaki; Maria C Jaimes; Tyson H Holmes; Cornelia L Dekker; Kutubuddin Mahmood; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

6.  Live attenuated versus inactivated influenza vaccine in infants and young children.

Authors:  Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

7.  Comparative efficacy of inactivated and live attenuated influenza vaccines.

Authors:  Arnold S Monto; Suzanne E Ohmit; Joshua G Petrie; Emileigh Johnson; Rachel Truscon; Esther Teich; Judy Rotthoff; Matthew Boulton; John C Victor
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.

Authors:  Z Moldoveanu; M L Clements; S J Prince; B R Murphy; J Mestecky
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

9.  Live attenuated and inactivated influenza vaccines in children.

Authors:  Natalia A Ilyushina; Brenda C Haynes; Anne G Hoen; Alexey M Khalenkov; Molly L Housman; Eric P Brown; Margaret E Ackerman; John J Treanor; Catherine J Luke; Kanta Subbarao; Peter F Wright
Journal:  J Infect Dis       Date:  2014-08-26       Impact factor: 5.226

10.  Influence of prior influenza vaccination on antibody and B-cell responses.

Authors:  Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  46 in total

Review 1.  The evolution of seasonal influenza viruses.

Authors:  Velislava N Petrova; Colin A Russell
Journal:  Nat Rev Microbiol       Date:  2017-10-30       Impact factor: 60.633

2.  Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret model.

Authors:  Daniil A Korenkov; Karen L Laurie; Patrick C Reading; Louise A Carolan; Kok Fei Chan; Irina I Isakova-Sivak; Tatiana A Smolonogina; Kanta Subbarao; Ian G Barr; Julie Villanueva; Svetlana Shcherbik; Tatiana Bousse; Larisa G Rudenko
Journal:  Infect Genet Evol       Date:  2018-06-19       Impact factor: 3.342

Review 3.  Inactivated influenza virus vaccines: the future of TIV and QIV.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Curr Opin Virol       Date:  2017-05-12       Impact factor: 7.090

4.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

Review 5.  Early programming and late-acting checkpoints governing the development of CD4 T-cell memory.

Authors:  Kunal Dhume; Karl Kai McKinstry
Journal:  Immunology       Date:  2018-05-21       Impact factor: 7.397

6.  Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site.

Authors:  Tatiana Kotomina; Daniil Korenkov; Victoria Matyushenko; Polina Prokopenko; Larisa Rudenko; Irina Isakova-Sivak
Journal:  Hum Vaccin Immunother       Date:  2018-08-29       Impact factor: 3.452

7.  Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.

Authors:  Sinthujan Jegaskanda; Rosemarie D Mason; Sarah F Andrews; Adam K Wheatley; Ruijun Zhang; Glennys V Reynoso; David R Ambrozak; Celia P Santos; Catherine J Luke; Yumiko Matsuoka; Jason M Brenchley; Heather D Hickman; Kawsar R Talaat; Sallie R Permar; Hua-Xin Liao; Jonathan W Yewdell; Richard A Koup; Mario Roederer; Adrian B McDermott; Kanta Subbarao
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

8.  Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.

Authors:  Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia
Journal:  JAMA Netw Open       Date:  2018-10-05

9.  Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.

Authors:  Yasuko Hatta; David Boltz; Sally Sarawar; Yoshihiro Kawaoka; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2018-07-13       Impact factor: 3.641

10.  IgA potentiates NETosis in response to viral infection.

Authors:  Hannah D Stacey; Diana Golubeva; Alyssa Posca; Jann C Ang; Kyle E Novakowski; Muhammad Atif Zahoor; Charu Kaushic; Ewa Cairns; Dawn M E Bowdish; Caitlin E Mullarkey; Matthew S Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.